{"gene":"RGS5","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":2001,"finding":"RGS5 binds Gαi1, Gαi2, Gαi3, Gαo, and Gαq (but not Gαs or Gα13) in the presence of GDP/AlF4-, and accelerates GTP hydrolysis by Gαi3, functioning as a GAP for these G-protein subunits. RGS5 suppresses angiotensin II- and endothelin-1-induced intracellular Ca2+ transients in AT1a-expressing cells. The N-terminal region (aa 1-33) targets RGS5 to membranes but is not essential for GAP activity.","method":"In vitro GTP hydrolysis assay, Gα-binding assay with GDP/AlF4-, Ca2+ signaling assay in 293T cells, subcellular fractionation","journal":"Life sciences","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro GAP reconstitution plus cell-based functional assays and subcellular fractionation, single lab with multiple orthogonal methods","pmids":["11253162"],"is_preprint":false},{"year":2002,"finding":"Endogenous RGS5 is a selective negative modulator of angiotensin AT1a receptor signaling through Gq/11 in rat vascular smooth muscle cells; RGS5 ribozyme knockdown specifically enhanced angiotensin II-induced MAP kinase activation and inositol phosphate release (pertussis toxin-insensitive), whereas RGS3 selectively modulated muscarinic m3 receptor signaling.","method":"Synthetic ribozyme-mediated knockdown, MAP kinase assay, inositol phosphate release assay in rat aortic smooth muscle cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function by ribozyme with specific phenotypic readout (MAPK, IP release), single lab, two orthogonal functional endpoints","pmids":["12006602"],"is_preprint":false},{"year":2003,"finding":"RGS5 acts as a potent GAP for Gαi and Gαq and attenuates angiotensin II-, endothelin-1-, sphingosine-1-phosphate-, and PDGF-induced ERK-2 phosphorylation in pericytes/VSMCs. RGS5 expression is pericyte-specific and depends on PDGF-B/PDGFRβ signaling for pericyte recruitment but is expressed independently of this pathway once pericytes are present.","method":"ERK-2 phosphorylation assay, in situ hybridization, mouse genetic models (PDGFR-β and PDGF-B knockout)","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional signaling assay combined with genetic model evidence, single lab, multiple orthogonal approaches","pmids":["12514120"],"is_preprint":false},{"year":2005,"finding":"RGS5 is degraded in vivo through the N-end rule ubiquitin-proteasome pathway: ATE1 Arg-transferase arginylates oxidized N-terminal Cys-2 of RGS5, generating an N-degron recognized by ubiquitin ligases UBR1 and UBR2. Mutation of Cys-2 prevents this modification and stabilizes RGS5. Hypoxia or loss of UBR1/UBR2 perturbs this degradation.","method":"In vivo degradation assay in ATE1-/- and UBR1/UBR2-null cells, Cys-2 mutant analysis, protein stability assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — mechanistic mutagenesis (C2 mutation), genetic knockouts of pathway components, replicated across multiple cell contexts in one rigorous study","pmids":["16217033"],"is_preprint":false},{"year":2005,"finding":"A human-specific alternatively spliced variant of RGS5 (RGS5s) lacks the N-terminal 108 amino acids, localizes almost exclusively to the cytosol (unlike full-length RGS5 which is in both membrane and cytosolic fractions), inhibits Gαi-coupled receptor (CB1) signaling but not Gαq-coupled AT1 or FP receptor Ca2+ signaling. Co-expression of RGS5s with RGS5 blocks RGS5-mediated inhibition of AT1 and FP receptor signaling, suggesting a dominant-negative or competitive mechanism.","method":"RT-PCR cloning, subcellular fractionation, Ca2+ signaling assay, co-transfection in HEK293 cells","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation with functional consequence, co-expression competition assay, single lab, multiple orthogonal methods","pmids":["15670159"],"is_preprint":false},{"year":2007,"finding":"PKC phosphorylates RGS5 at Ser166 (identified by mass spectrometry), and this phosphorylation abolishes Gα-subunit binding and GAP activity. Substitution of Ser166 with aspartate (phospho-mimetic) markedly reduced inhibition of ET-1-induced Ca2+ responses; PKC inhibitors enhanced RGS5 inhibitory function.","method":"In vitro PKC phosphorylation assay, mass spectrometry, site-directed mutagenesis (S166D), Gα binding assay, Ca2+ signaling assay","journal":"Life sciences","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with MS identification of phospho-site, mutagenesis validation, cell-based functional readout; single lab but multiple orthogonal methods","pmids":["17540411"],"is_preprint":false},{"year":2007,"finding":"N-terminal residues control proteasomal degradation of RGS5 in HEK293 cells; a stabilizing C2S mutation enhances RGS5 expression and function, whereas wild-type RGS5 has minimal cellular expression due to rapid N-end rule-mediated degradation.","method":"Mutagenesis, proteasome inhibitor treatment, expression/functional assays in HEK293 cells","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — mutagenesis and cell-based expression assay confirming N-end rule mechanism, single lab","pmids":["17220356"],"is_preprint":false},{"year":1999,"finding":"The N-terminal amphipathic alpha-helix (aa 12-30) of RGS16 is required for plasma membrane association, and the hydrophobic residues on the nonpolar face plus positively charged residues at the polar/nonpolar interface are critical; RGS5 contains a homologous domain predicted to mediate membrane association by the same mechanism. RGS16 (and by homology RGS5) is a peripheral membrane protein not requiring palmitoylation.","method":"Site-directed mutagenesis, subcellular fractionation, differential centrifugation, alkaline wash (peripheral membrane protein characterization)","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous mutagenesis and fractionation for RGS16, structural inference extended to RGS5 by homology without direct RGS5 experiments in this paper","pmids":["10391923"],"is_preprint":false},{"year":2008,"finding":"Rgs5-deficient mice have persistently low blood pressure and dilated aortas. Isolated aortic smooth muscle cells from Rgs5-/- mice show exaggerated ERK phosphorylation and VASP phosphorylation in response to nitric oxide donor (sodium nitroprusside) or sphingosine-1-phosphate, indicating RGS5 attenuates vasodilatory signaling in vivo.","method":"Rgs5 knockout mouse, blood pressure telemetry, aortic morphometry, ex vivo smooth muscle cell signaling assays (western blot for pVASP, pERK)","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO mouse with defined vascular phenotype and ex vivo mechanistic signaling readouts, single lab, multiple orthogonal endpoints","pmids":["18268011"],"is_preprint":false},{"year":2008,"finding":"Loss of Rgs5 in tumors results in pericyte maturation and vascular normalization (reduced vessel leakiness, reduced hypoxia), enhancing immune effector cell influx into tumors and prolonging survival of tumor-bearing mice, establishing RGS5 as a master regulator of abnormal tumor vascular morphology.","method":"Rgs5 knockout mouse in tumor models, MRI/histological vascular analysis, immune cell infiltration assay, survival analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with multiple functional vascular and immunological phenotypic readouts; high-impact replication context","pmids":["18418378"],"is_preprint":false},{"year":2009,"finding":"Under hypoxia, RGS5 expression in endothelial cells is induced via HIF-1α-dependent transcription (RGS5 promoter activity is absent in HIF-1β-/- cells). RGS5 overexpression induces endothelial apoptosis via caspase-3 activation and increased Bax/Bcl-2 ratio. RGS5 augments VEGF-mediated p38 (but not ERK1/2) activation and impairs VEGF-induced angiogenesis in Matrigel assay.","method":"HIF-1β-/- cell promoter assay, RGS5 overexpression/siRNA knockdown in HUVEC, Annexin V apoptosis assay, caspase-3 activity assay, p38/ERK western blot, Matrigel angiogenesis assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (HIF-1β-/-) plus OE/KD with multiple functional readouts, single lab","pmids":["19564336"],"is_preprint":false},{"year":2011,"finding":"Beta-agonist treatment of human airway smooth muscle cells decreases RGS5 expression. RGS5 knockdown increases agonist-evoked intracellular calcium flux and myosin light chain phosphorylation. Airway smooth muscle from Rgs5-/- mice contracts more to carbachol than WT, establishing RGS5 as a negative regulator of bronchial smooth muscle contraction.","method":"siRNA knockdown in human airway smooth muscle cells, Ca2+ flux assay, MLC phosphorylation assay, precision-cut lung slice contraction in Rgs5-/- mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — KD in human cells plus KO mouse tissue with consistent phenotypic readout across two systems; single lab but replicated across two orthogonal models","pmids":["21278382"],"is_preprint":false},{"year":2012,"finding":"PPARγ and PPARδ each bind a PPAR response element near the RGS5 promoter and transcriptionally regulate RGS5 expression in vascular smooth muscle cells. RGS5, as a PPARγ/δ target, blunts angiotensin II-mediated PKC activation and preserves large-conductance Ca2+-activated K+ (BKCa) channel activity, controlling myogenic tone in resistance arteries.","method":"Chromatin reporter assay (PPRE), siRNA knockdown of RGS5, patch-clamp of BKCa current, myogenic tone measurement, transgenic dominant-negative PPARγ SMC mice, gene expression profiling","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — transcriptional mechanism (PPRE binding), patch-clamp electrophysiology, siRNA knockdown with functional phenotype, transgenic mouse model; multiple orthogonal methods, single lab","pmids":["22962432"],"is_preprint":false},{"year":2012,"finding":"Rgs5-/- mice show prolonged cardiac repolarization (prolonged QT interval and action potential duration) and increased susceptibility to ventricular tachyarrhythmia. This correlates with reduced outward K+ currents (Ito, IKur, Iss, Ipeak) and downregulated expression of Kv4.2, Kv4.3, Kv1.5, and Kv2.1 channels in ventricular myocytes.","method":"Rgs5 knockout mouse, in vivo/ex vivo electrocardiography, whole-cell patch clamp in ventricular myocytes, protein/mRNA expression analysis","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO mouse with patch-clamp electrophysiology defining K+ channel remodeling mechanism, single lab, multiple orthogonal methods","pmids":["23079193"],"is_preprint":false},{"year":2013,"finding":"RGS5 is an endogenous repressor of Hedgehog signaling: RGS5 overexpression inhibits Shh-mediated signaling and osteogenesis, while siRNA knockdown of RGS5 (but not RGS4) potentiates Shh signaling. RGS5 co-localizes with Smoothened in primary cilia and co-immunoprecipitates with Smo, placing RGS5 downstream of Smo as a GAP for Gαi in the Hh pathway.","method":"RGS5 overexpression and siRNA knockdown in C3H10T1/2 cells, co-immunoprecipitation, immunohistochemistry of primary cilia, osteogenesis assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP showing physical complex with Smo, loss- and gain-of-function with defined signaling phenotype, single lab, two orthogonal methods","pmids":["23637832"],"is_preprint":false},{"year":2014,"finding":"RGS5 is upregulated in vascular SMCs of remodeling collateral arterioles during arteriogenesis. RGS5 overexpression blunts Gαq/11-mediated Ca2+ mobilization and facilitates Gα12/13-mediated RhoA signaling, promoting SMC proliferation and acquisition of the activated phenotype required for collateral growth. RGS5 knockdown blocks RhoA activation, SMC proliferation, and collateral arteriole growth.","method":"RGS5 overexpression/knockdown in VSMCs, intracellular Ca2+ assay, RhoA activity assay (G-LISA/pull-down), mouse arteriogenesis model (femoral artery ligation), RGS5-deficient mice","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss- and gain-of-function with mechanistic signaling readouts (Ca2+, RhoA) in vitro plus in vivo arteriogenesis model, single lab, multiple orthogonal methods","pmids":["24972930"],"is_preprint":false},{"year":2015,"finding":"GPSM3 selectively binds RGS5 (not RGS4 or other RGS proteins tested) and enhances RGS5's ability to accelerate GTP hydrolysis by Gαi1 in solution-based assays. In membrane-based assays with M2 receptor-activated Gαi1, GPSM3 does not inhibit RGS5 GAP activity (unlike its effect on RGS4), suggesting binding of GPSM3 to RGS5 maintains or enhances GAP activity.","method":"Co-immunoprecipitation/pulldown, in vitro GTP hydrolysis assay (solution-based and membrane-based), primary rat aortic smooth muscle cell expression analysis","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro GAP assay with identified binding partner, single lab, no independent replication","pmids":["25842189"],"is_preprint":false},{"year":2017,"finding":"In vascular smooth muscle cells, AT1R activation by angiotensin II or mechanical stimulation (hypotonic solution) induces translocation/trafficking of RGS5 toward the plasma membrane to co-localize with the activated AT1R (demonstrated by proximity ligation assay). RGS5 knockdown enhances constriction to angiotensin II and augments myogenic responses. This trafficking is impaired in VSMCs from spontaneously hypertensive rats.","method":"In situ proximity ligation assay, siRNA knockdown of RGS5 in arteriolar VSMCs, myogenic constriction measurement, intact arteriole contractility","journal":"Hypertension","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity ligation assay showing receptor-RGS5 interaction, siRNA KD with functional phenotype; single lab, two orthogonal methods","pmids":["29061726"],"is_preprint":false},{"year":2017,"finding":"RGS5 inhibits Shh function in cortical neurons: RGS5 overexpression via adenovirus reduces neurite outgrowth and FM4-64 uptake (presynaptic terminal maturation marker), and affects cAMP-PKA signaling in cortical neurons, suggesting RGS5 acts as a Gαi GAP downstream of Smoothened in neuronal hedgehog signaling.","method":"Adenoviral RGS5 overexpression in primary cortical neurons, neurite outgrowth measurement, FM4-64 uptake assay, cAMP assay","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — gain-of-function with defined neuronal phenotypic readouts, single lab, single method per endpoint","pmids":["28684360"],"is_preprint":false},{"year":2018,"finding":"Hypertensive pressure levels or biomechanical stretch increase RGS5 expression in VSMCs. RGS5 is required for hypertension-induced RhoA activation and stress fiber formation; RGS5-deficient VSMCs fail to acquire a synthetic phenotype (cannot downregulate α-SMA, smooth muscle-MHC, or proliferate) under hypertensive conditions. PKC inhibition mimics the downstream effect of RGS5-mediated Gαq/11 inhibition, amplifying RhoA activity.","method":"RGS5-deficient mice with experimental hypertension (angiotensin II infusion), mechanical stretch assay in VSMCs, RhoA activity assay, contractile marker western blot, PKC inhibitor experiments","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO mouse plus in vitro stretch/pharmacological dissection with mechanistic pathway (RhoA/PKC), single lab, multiple orthogonal methods","pmids":["29208700"],"is_preprint":false},{"year":2021,"finding":"RGS5 binds Gαi/q and promotes pericyte apoptosis in vitro by blocking PI3K-AKT signaling, leading to Bcl2 downregulation and PUMA-p53-Bax-mediated mitochondrial damage. Within the tumor microenvironment, TGFβ causes pSmad2 to bind RGS5 and translocate it to the nucleus, suppressing both RGS5-Gαi/q interaction and pSmad2/3-Smad4 pairing, thereby rescuing PI3K-AKT survival signaling and preventing apoptosis in tumor pericytes.","method":"Co-immunoprecipitation of RGS5 with Gαi/q and pSmad2, nuclear fractionation, PI3K-AKT/Bcl2/Bax western blot, caspase assay, siRNA/overexpression in pericytes, TGFβ treatment","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying molecular complex, nuclear translocation, multiple signaling pathway readouts; single lab, several orthogonal methods","pmids":["34012071"],"is_preprint":false},{"year":2021,"finding":"ATE1-mediated arginylation controls RGS5 protein turnover and thereby regulates Wnt/β-catenin signaling in liver cancer cells: ATE1 overexpression accelerates β-catenin degradation through RGS5-dependent regulation of GSK3-β activity; RGS5 knockdown reverses ATE1-mediated suppression of Wnt signaling. Co-immunoprecipitation confirms RGS5 interaction with components of this pathway.","method":"ATE1/RGS5 loss- and gain-of-function in HCC cells, β-catenin western blot, GSK3-β activity assay, GSK inhibitor rescue experiment, co-immunoprecipitation","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis experiments placing RGS5 between ATE1 and Wnt/β-catenin, Co-IP, GSK inhibitor rescue; single lab","pmids":["34158395"],"is_preprint":false},{"year":2021,"finding":"RGS5 overexpression in proliferating VSMCs attenuates ERK1/2 and Akt signaling, reduces proliferation and migration; this effect is mimicked by selective Gαi/o inhibition but not by Gαq/11 inhibition, indicating RGS5 maintains VSMC resting state principally by suppressing Gαi/o-mediated ERK1/2 activation.","method":"RGS5 overexpression in 2D-cultured VSMCs, Gαi/o- and Gαq/11-selective inhibitors, ERK1/2/Akt phosphorylation western blot, proliferation and migration assays, microarray expression profiling","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of G-protein subtype specificity combined with OE and functional readouts; single lab, multiple orthogonal approaches","pmids":["34359918"],"is_preprint":false},{"year":2021,"finding":"RGS5 deletion in neutrophils impairs their migration toward chemokines despite preserved Ca2+ signaling; ERK dephosphorylation is implicated in reduced neutrophil migration. In vivo, RGS5-/- mice fail to recruit neutrophils to the lung after bleomycin or LPS injury, preserving lung function.","method":"RGS5-/- mouse lung injury models (bleomycin, LPS), in vitro neutrophil migration assay, Ca2+ signaling measurement, ERK phosphorylation western blot, myeloperoxidase measurement","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse plus in vitro mechanistic dissection (Ca2+, ERK) of migration defect; single lab","pmids":["34502263"],"is_preprint":false},{"year":2023,"finding":"In astrocytes, RGS5 promotes neuroinflammation by binding directly to TNFR1 and TNFR2 (shown by Co-IP), augmenting TNF receptor signaling and switching astrocytes from neuroprotective to pro-inflammatory. Selective ablation of Rgs5 in astrocytes inhibits cytokine production and is neuroprotective in PD models; the RGS5 aa 1-108 fragment or small molecules (feshurin, butein) that disrupt RGS5/TNFR interaction suppress astrocytic cytokine production.","method":"Conditional astrocyte-specific Rgs5 knockout, RGS5 overexpression, Co-IP of RGS5 with TNFR1/TNFR2, cytokine ELISA, PD mouse models, competitive peptide/small molecule inhibition","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO plus reciprocal Co-IP showing direct protein-protein interaction with TNFRs plus pharmacological disruption; single lab, multiple orthogonal methods","pmids":["37674228"],"is_preprint":false},{"year":2023,"finding":"RGS5 in cardiac pericytes is reduced with aging. Deletion of RGS5 causes cardiac dysfunction and myocardial fibrosis by inducing a profibrotic gene signature in pericytes (upregulating TGFB2, PDGFB, ECM components). Conditioned medium from RGS5-deficient pericytes activates adjacent fibroblasts (increased αSMA) via a TGFβ2-dependent mechanism.","method":"Pericyte-specific RGS5 deletion in mice, single-nucleus RNA sequencing, pericyte-fibroblast co-culture, conditioned medium experiments, αSMA/TGFβ2 western blot, cardiac function echocardiography, fibrosis histology","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo KO phenotype plus mechanistic co-culture demonstrating TGFβ2-dependent paracrine fibroblast activation, snRNA-seq; single lab, multiple orthogonal methods","pmids":["38563133"],"is_preprint":false},{"year":2019,"finding":"RGS5 overexpression in parathyroid cells inhibits calcium-sensing receptor (CASR) signaling and impairs negative feedback on PTH secretion. Transgenic mice overexpressing RGS5 specifically in parathyroid glands develop hyperparathyroidism, bone changes, and parathyroid neoplasia, establishing RGS5 as an inhibitor of CASR-mediated signaling in parathyroid physiology.","method":"Parathyroid-specific RGS5 transgenic mouse, PTH measurement, bone analysis, parathyroid histology, CASR signaling assay in normal human parathyroid cells expressing RGS5","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — transgenic gain-of-function mouse with organ-specific phenotype plus cell-based CASR signaling assay; single lab, multiple orthogonal methods","pmids":["30690792"],"is_preprint":false},{"year":2006,"finding":"The complex of human Gαi3 and RGS5 was crystallized with GDP/Mg2+/AlF4- at 3.0 Å resolution (space group P4(1)2(1)2 or P4(3)2(1)2), providing preliminary structural data for the RGS5-Gα interaction.","method":"Recombinant protein expression in E. coli, protein purification, X-ray crystallography (synchrotron, 3.0 Å)","journal":"Protein and peptide letters","confidence":"Low","confidence_rationale":"Tier 1 / Weak — preliminary crystallization report without full structural analysis or functional validation; single paper, no replication","pmids":["17100651"],"is_preprint":false},{"year":2007,"finding":"RGS5 forms homodimers detectable by western blot (~42 kDa band) and confirmed by yeast two-hybrid and GFP-tagged RGS5 analysis in HEK293A cells. The dimer is longer-lived than the monomer, suggesting a regulatory function.","method":"Western blot of overexpressed RGS5, yeast two-hybrid assay, GFP-RGS5 fusion analysis in yeast and HEK293A cells","journal":"Cellular physiology and biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast two-hybrid and western blot evidence for dimerization, functional significance not established; single lab, single study","pmids":["17762159"],"is_preprint":false},{"year":2011,"finding":"Rgs5 expression shows vascular bed-specific differences in adult mice driven by an origin-specific epigenetic program: the Rgs5 promoter is more heavily methylated at CpG dinucleotides in carotid artery (neural crest-derived) VSMCs compared to descending aorta VSMCs in adults but not neonates. In vitro methylation of the Rgs5 promoter confirmed transcriptional repression by CpG methylation.","method":"Rgs5-LacZ reporter mouse (lineage mapping), bisulfite sequencing of Rgs5 promoter, in vitro methylation reporter assay, primary VSMC culture","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — bisulfite sequencing identifying specific CpG methylation plus in vitro promoter methylation functional assay plus LacZ reporter in vivo; single lab, multiple orthogonal methods","pmids":["21965603"],"is_preprint":false}],"current_model":"RGS5 is a GTPase-activating protein (GAP) for Gαi and Gαq subunits, expressed predominantly in pericytes and vascular smooth muscle cells, whose protein stability is regulated by the N-end rule pathway (ATE1-mediated arginylation of oxidized Cys-2 followed by UBR1/UBR2-dependent ubiquitination and proteasomal degradation); PKC phosphorylation at Ser166 inactivates its GAP function; in VSMCs it suppresses Gαq/11-mediated calcium signaling while enabling Gα12/13/RhoA-dependent SMC activation, thereby regulating arterial tone, vascular remodeling, arteriogenesis, and hypertension responses; in pericytes it controls vessel maturation, tumor vascular morphology, and cardiac homeostasis partly through TGFβ/Smad2-regulated nuclear trafficking; and in non-vascular contexts it functions as a repressor of Hedgehog/Gαi signaling and, in astrocytes, augments TNF receptor signaling through direct TNFR1/TNFR2 binding to promote neuroinflammation."},"narrative":{"mechanistic_narrative":"RGS5 is a GTPase-activating protein (GAP) that accelerates GTP hydrolysis by Gαi and Gαq subunits and thereby acts as a negative regulator of G-protein-coupled receptor signaling, with a predominant role in vascular smooth muscle and pericyte biology [PMID:11253162, PMID:12514120]. Through GAP activity on Gαq/11 it dampens angiotensin II- and endothelin-1-evoked intracellular Ca2+ transients and downstream MAPK signaling in vascular smooth muscle cells [PMID:11253162, PMID:12006602, PMID:12514120], and upon receptor activation or mechanical stimulation it traffics to the plasma membrane to co-localize with the activated AT1 receptor [PMID:29061726]. In vivo, RGS5 sets vascular tone and blood pressure: Rgs5-null mice are hypotensive with dilated aortas and show exaggerated vasodilatory ERK/VASP signaling [PMID:18268011], while in resistance arteries RGS5 (a transcriptional target of PPARγ/δ) blunts angiotensin II-driven PKC activation and preserves BKCa channel activity to control myogenic tone [PMID:22962432]. By simultaneously suppressing Gαq/11-Ca2+ signaling and licensing Gα12/13-RhoA signaling, RGS5 drives the phenotypic switch of smooth muscle cells required for arteriogenesis and hypertensive remodeling [PMID:24972930, PMID:29208700]. In pericytes RGS5 governs tumor vessel morphology—its loss promotes pericyte maturation, vascular normalization, and enhanced anti-tumor immune infiltration [PMID:18418378]—and it controls pericyte survival and cardiac homeostasis, where TGFβ-driven pSmad2 binding redirects RGS5 to the nucleus to rescue PI3K-AKT survival signaling, and where pericyte RGS5 loss elicits a TGFβ2-dependent profibrotic program [PMID:34012071, PMID:38563133]. RGS5 protein abundance is tightly governed by the N-end rule pathway: ATE1 arginylates oxidized N-terminal Cys-2 to generate an N-degron recognized by the UBR1/UBR2 ubiquitin ligases for proteasomal degradation, and a stabilizing Cys-2 mutation increases RGS5 expression and function [PMID:16217033, PMID:17220356]. GAP activity is further switched off by PKC phosphorylation at Ser166, which abolishes Gα binding [PMID:17540411]. Beyond the vasculature, RGS5 represses Hedgehog/Gαi signaling in association with Smoothened at the primary cilium [PMID:23637832], and in astrocytes it binds TNFR1 and TNFR2 directly to augment TNF receptor signaling and promote neuroinflammation [PMID:37674228].","teleology":[{"year":2001,"claim":"Established RGS5's core biochemical identity by showing it is a GAP selective for Gαi and Gαq subunits that dampens receptor-evoked calcium signaling, defining the molecular activity all later vascular roles build on.","evidence":"In vitro GTP hydrolysis and Gα-binding assays plus Ca2+ signaling and fractionation in 293T cells","pmids":["11253162"],"confidence":"High","gaps":["Did not establish the physiological receptor/tissue context","Membrane-targeting role of N-terminus separated from GAP catalysis but not structurally resolved"]},{"year":2002,"claim":"Showed endogenous RGS5 selectively constrains AT1 receptor-Gq/11 signaling in vascular smooth muscle, moving from biochemistry to a defined endogenous receptor target.","evidence":"Ribozyme knockdown with MAPK and inositol phosphate readouts in rat aortic smooth muscle cells","pmids":["12006602"],"confidence":"Medium","gaps":["Single loss-of-function approach","In vivo relevance not yet tested"]},{"year":2003,"claim":"Defined RGS5 as a pericyte-specific gene downstream of PDGF-B/PDGFRβ-driven pericyte recruitment, localizing its biology to the pericyte/VSMC compartment.","evidence":"ERK assays, in situ hybridization, and PDGFRβ/PDGF-B knockout mice","pmids":["12514120"],"confidence":"Medium","gaps":["Mechanism coupling pericyte identity to RGS5 transcription unresolved"]},{"year":2005,"claim":"Revealed that RGS5 abundance is controlled post-translationally by the N-end rule pathway via ATE1 arginylation of oxidized Cys-2 and UBR1/UBR2-dependent ubiquitination, explaining its normally low cellular levels and oxygen sensitivity.","evidence":"In vivo degradation assays in ATE1-/- and UBR1/UBR2-null cells with Cys-2 mutagenesis","pmids":["16217033"],"confidence":"High","gaps":["How physiological hypoxia tunes RGS5 stability in vascular cells not directly measured","Did not link degradation rate to a specific GAP-dependent phenotype"]},{"year":2005,"claim":"Identified a human-specific cytosolic splice variant lacking the N-terminal 108 residues that selectively inhibits Gαi signaling and can competitively block full-length RGS5, introducing isoform-level regulation of GAP specificity.","evidence":"RT-PCR cloning, fractionation, and co-transfection Ca2+ assays in HEK293 cells","pmids":["15670159"],"confidence":"Medium","gaps":["Endogenous abundance and in vivo role of the variant unknown","Dominant-negative mechanism inferred from overexpression"]},{"year":2007,"claim":"Showed PKC phosphorylation at Ser166 abolishes Gα binding and GAP activity, providing an acute signaling switch that inactivates RGS5 independent of its degradation.","evidence":"In vitro PKC kinase assay, mass spectrometry, S166D mutant, and Ca2+ signaling readouts","pmids":["17540411"],"confidence":"High","gaps":["Which receptors/PKC isoforms drive Ser166 phosphorylation in vivo not defined"]},{"year":2008,"claim":"Demonstrated in vivo that RGS5 sets blood pressure and vascular tone, with knockout causing hypotension, aortic dilation, and exaggerated vasodilatory signaling.","evidence":"Rgs5 knockout mice with telemetry, morphometry, and ex vivo pVASP/pERK signaling","pmids":["18268011"],"confidence":"High","gaps":["Receptor coupling underlying enhanced NO/S1P responses not pinpointed"]},{"year":2008,"claim":"Established RGS5 as a master regulator of abnormal tumor vasculature, where its loss normalizes vessels and improves immune infiltration and survival.","evidence":"Rgs5 knockout tumor models with vascular imaging, immune infiltration, and survival analysis","pmids":["18418378"],"confidence":"High","gaps":["Cell-autonomous pericyte signaling driving normalization not dissected in this study"]},{"year":2012,"claim":"Placed RGS5 in transcriptional and electrophysiological control of myogenic tone as a PPARγ/δ target that preserves BKCa channel activity by limiting angiotensin II-PKC signaling.","evidence":"PPRE reporter, siRNA, BKCa patch-clamp, myogenic tone, and dominant-negative PPARγ mice","pmids":["22962432"],"confidence":"High","gaps":["Direct link from RGS5 GAP activity to BKCa modulation mechanistically incomplete"]},{"year":2014,"claim":"Resolved the dual G-protein logic of RGS5 in arteriogenesis: it suppresses Gαq/11-Ca2+ while facilitating Gα12/13-RhoA signaling to drive the activated, proliferative SMC phenotype.","evidence":"Gain/loss-of-function in VSMCs with Ca2+ and RhoA assays plus a femoral ligation arteriogenesis model","pmids":["24972930"],"confidence":"High","gaps":["How a GAP promotes rather than inhibits Gα12/13-RhoA signaling not mechanistically explained"]},{"year":2018,"claim":"Extended the RhoA-licensing role to hypertensive remodeling, showing RGS5 is required for stress-fiber formation and synthetic phenotype switching under pressure.","evidence":"RGS5-deficient mice with angiotensin II infusion, stretch assays, RhoA activity, and PKC inhibition","pmids":["29208700"],"confidence":"High","gaps":["Whether nuclear or membrane RGS5 mediates the remodeling phenotype unresolved"]},{"year":2017,"claim":"Linked RGS5 function to receptor-triggered subcellular trafficking, showing it moves to the activated AT1R at the membrane and that this trafficking is impaired in hypertensive vessels.","evidence":"Proximity ligation assay and siRNA knockdown with myogenic constriction in arteriolar VSMCs","pmids":["29061726"],"confidence":"Medium","gaps":["Molecular driver of RGS5 translocation not identified","Correlative link to hypertension"]},{"year":2015,"claim":"Identified GPSM3 as a selective RGS5-binding partner that maintains or enhances RGS5 GAP activity, distinguishing RGS5 regulation from other RGS proteins.","evidence":"Co-IP/pulldown and solution/membrane GTP hydrolysis assays","pmids":["25842189"],"confidence":"Medium","gaps":["No independent replication","Physiological consequence of GPSM3-RGS5 complex not tested"]},{"year":2021,"claim":"Defined a tumor-microenvironment switch in which TGFβ-driven pSmad2 binds RGS5 and translocates it to the nucleus, releasing Gαi/q to rescue PI3K-AKT survival signaling in pericytes.","evidence":"Co-IP of RGS5 with Gαi/q and pSmad2, nuclear fractionation, and apoptosis/PI3K-AKT readouts in pericytes","pmids":["34012071"],"confidence":"Medium","gaps":["Direct demonstration that nuclear sequestration causes the survival phenotype is indirect","Single lab"]},{"year":2023,"claim":"Connected pericyte RGS5 loss to cardiac dysfunction and fibrosis via a TGFβ2-dependent paracrine profibrotic program, extending its pericyte role to organ homeostasis.","evidence":"Pericyte-specific RGS5 deletion, snRNA-seq, and pericyte-fibroblast co-culture/conditioned medium experiments","pmids":["38563133"],"confidence":"High","gaps":["How RGS5 GAP activity represses the profibrotic transcriptional program not resolved"]},{"year":2013,"claim":"Placed RGS5 outside the vasculature as an endogenous Hedgehog repressor acting as a Gαi GAP in complex with Smoothened at the primary cilium.","evidence":"Overexpression/siRNA, Co-IP with Smo, and ciliary co-localization in C3H10T1/2 cells","pmids":["23637832"],"confidence":"Medium","gaps":["Direct GAP action on Smo-coupled Gαi at the cilium inferred, not biochemically reconstituted"]},{"year":2023,"claim":"Revealed a non-GAP signaling role in astrocytes where RGS5 binds TNFR1/TNFR2 directly to augment TNF signaling and drive neuroinflammation, identifying a druggable protein-protein interaction.","evidence":"Astrocyte-specific knockout, reciprocal Co-IP with TNFRs, PD models, and peptide/small-molecule disruption","pmids":["37674228"],"confidence":"High","gaps":["Structural basis of RGS5-TNFR binding undefined","Relationship between TNFR binding and canonical GAP activity unclear"]},{"year":null,"claim":"How RGS5 reconciles its dual roles as a GAP that both inhibits (Gαq/11, Gαi) and enables (Gα12/13-RhoA) signaling, and how its trafficking, dimerization, and non-GAP TNFR/Smo binding are integrated at the structural level, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full atomic-resolution RGS5-Gα structure analyzed beyond preliminary crystallization","Functional significance of RGS5 homodimerization unestablished","Mechanism by which a GAP facilitates Gα12/13-RhoA signaling unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2,5,16]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,14,24]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,7,17]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,4]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[20]},{"term_id":"GO:0005929","term_label":"cilium","supporting_discovery_ids":[14]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,14,15]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,6]},{"term_id":"R-HSA-397014","term_label":"Muscle contraction","supporting_discovery_ids":[11,12,19]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[24,23]}],"complexes":[],"partners":["GNAI1","GNAI3","GNAQ","GPSM3","SMO","TNFRSF1A","TNFRSF1B","SMAD2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15539","full_name":"Regulator of G-protein signaling 5","aliases":[],"length_aa":181,"mass_kda":20.9,"function":"Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form. Binds to G(i)-alpha and G(o)-alpha, but not to G(s)-alpha (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/O15539/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RGS5","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RGS5","total_profiled":1310},"omim":[{"mim_id":"611392","title":"2-@AMINOETHANETHIOL DIOXYGENASE; ADO","url":"https://www.omim.org/entry/611392"},{"mim_id":"607103","title":"ARGINYLTRANSFERASE 1; ATE1","url":"https://www.omim.org/entry/607103"},{"mim_id":"603276","title":"REGULATOR OF G PROTEIN SIGNALING 5; RGS5","url":"https://www.omim.org/entry/603276"},{"mim_id":"182330","title":"ATPase, Na+/K+ TRANSPORTING, BETA-1 POLYPEPTIDE; ATP1B1","url":"https://www.omim.org/entry/182330"},{"mim_id":"145500","title":"HYPERTENSION, ESSENTIAL","url":"https://www.omim.org/entry/145500"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":1362.9}],"url":"https://www.proteinatlas.org/search/RGS5"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O15539","domains":[{"cath_id":"1.10.167.10","chopping":"56-181","consensus_level":"medium","plddt":97.5971,"start":56,"end":181}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15539","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15539-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15539-F1-predicted_aligned_error_v6.png","plddt_mean":85.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RGS5","jax_strain_url":"https://www.jax.org/strain/search?query=RGS5"},"sequence":{"accession":"O15539","fasta_url":"https://rest.uniprot.org/uniprotkb/O15539.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15539/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15539"}},"corpus_meta":[{"pmid":"18418378","id":"PMC_18418378","title":"Vascular normalization in Rgs5-deficient tumours promotes immune destruction.","date":"2008","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/18418378","citation_count":455,"is_preprint":false},{"pmid":"16217033","id":"PMC_16217033","title":"RGS4 and RGS5 are in vivo substrates of the N-end rule pathway.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16217033","citation_count":230,"is_preprint":false},{"pmid":"12598306","id":"PMC_12598306","title":"Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12598306","citation_count":192,"is_preprint":false},{"pmid":"12514120","id":"PMC_12514120","title":"Pericyte-specific expression of Rgs5: implications for PDGF and EDG receptor signaling during vascular maturation.","date":"2003","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12514120","citation_count":161,"is_preprint":false},{"pmid":"12006602","id":"PMC_12006602","title":"Receptor-selective effects of endogenous RGS3 and RGS5 to regulate mitogen-activated protein kinase activation in rat vascular smooth muscle cells.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12006602","citation_count":99,"is_preprint":false},{"pmid":"10391923","id":"PMC_10391923","title":"The membrane association domain of RGS16 contains unique amphipathic features that are conserved in RGS4 and RGS5.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10391923","citation_count":89,"is_preprint":false},{"pmid":"18268011","id":"PMC_18268011","title":"Rgs5 targeting leads to chronic low blood pressure and a lean body habitus.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18268011","citation_count":77,"is_preprint":false},{"pmid":"17220356","id":"PMC_17220356","title":"N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells.","date":"2007","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17220356","citation_count":76,"is_preprint":false},{"pmid":"18038251","id":"PMC_18038251","title":"RGS5 expression is a quantitative measure of pericyte coverage of blood vessels.","date":"2007","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18038251","citation_count":72,"is_preprint":false},{"pmid":"11253162","id":"PMC_11253162","title":"Characterization of RGS5 in regulation of G protein-coupled receptor signaling.","date":"2001","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11253162","citation_count":70,"is_preprint":false},{"pmid":"18212066","id":"PMC_18212066","title":"Generation and characterization of rgs5 mutant mice.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18212066","citation_count":68,"is_preprint":false},{"pmid":"19564336","id":"PMC_19564336","title":"RGS5, a hypoxia-inducible apoptotic stimulator in endothelial cells.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19564336","citation_count":62,"is_preprint":false},{"pmid":"15095478","id":"PMC_15095478","title":"Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma.","date":"2004","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15095478","citation_count":61,"is_preprint":false},{"pmid":"22962432","id":"PMC_22962432","title":"PPARγ regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity.","date":"2012","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/22962432","citation_count":55,"is_preprint":false},{"pmid":"17939118","id":"PMC_17939118","title":"Coexpression of Notch3 and Rgs5 in the pericyte-vascular smooth muscle cell axis in response to pulp injury.","date":"2007","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17939118","citation_count":53,"is_preprint":false},{"pmid":"36982915","id":"PMC_36982915","title":"Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36982915","citation_count":52,"is_preprint":false},{"pmid":"9747037","id":"PMC_9747037","title":"Isolation, tissue expression, and chromosomal assignment of human RGS5, a novel G-protein signaling regulator gene.","date":"1998","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9747037","citation_count":49,"is_preprint":false},{"pmid":"22130514","id":"PMC_22130514","title":"Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment.","date":"2011","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/22130514","citation_count":42,"is_preprint":false},{"pmid":"17545542","id":"PMC_17545542","title":"Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17545542","citation_count":39,"is_preprint":false},{"pmid":"16293795","id":"PMC_16293795","title":"Expression profiling identifies smooth muscle cell diversity within human intima and plaque fibrous cap: loss of RGS5 distinguishes the cap.","date":"2005","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16293795","citation_count":39,"is_preprint":false},{"pmid":"18207159","id":"PMC_18207159","title":"RGS5, RGS4, and RGS2 expression and aortic contractibility are dynamically co-regulated during aortic banding-induced hypertrophy.","date":"2007","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/18207159","citation_count":34,"is_preprint":false},{"pmid":"34012071","id":"PMC_34012071","title":"RGS5-TGFβ-Smad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/34012071","citation_count":32,"is_preprint":false},{"pmid":"24972930","id":"PMC_24972930","title":"RGS5 promotes arterial growth during arteriogenesis.","date":"2014","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24972930","citation_count":31,"is_preprint":false},{"pmid":"39306871","id":"PMC_39306871","title":"RGS5+ lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism.","date":"2024","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/39306871","citation_count":30,"is_preprint":false},{"pmid":"21780128","id":"PMC_21780128","title":"The relationship between RGS5 expression and cancer differentiation and metastasis in non-small cell lung cancer.","date":"2011","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21780128","citation_count":29,"is_preprint":false},{"pmid":"21881522","id":"PMC_21881522","title":"Association of ATP1B1, RGS5 and SELE polymorphisms with hypertension and blood pressure in African-Americans.","date":"2011","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/21881522","citation_count":29,"is_preprint":false},{"pmid":"21965603","id":"PMC_21965603","title":"Origin-specific epigenetic program correlates with vascular bed-specific differences in Rgs5 expression.","date":"2011","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/21965603","citation_count":29,"is_preprint":false},{"pmid":"17986358","id":"PMC_17986358","title":"Vascular microarray profiling in two models of hypertension identifies caveolin-1, Rgs2 and Rgs5 as antihypertensive targets.","date":"2007","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17986358","citation_count":29,"is_preprint":false},{"pmid":"21278382","id":"PMC_21278382","title":"Beta-agonist-associated reduction in RGS5 expression promotes airway smooth muscle hyper-responsiveness.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21278382","citation_count":27,"is_preprint":false},{"pmid":"18262772","id":"PMC_18262772","title":"Association of RGS2 and RGS5 variants with schizophrenia symptom severity.","date":"2008","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/18262772","citation_count":27,"is_preprint":false},{"pmid":"38563133","id":"PMC_38563133","title":"Age-Dependent RGS5 Loss in Pericytes Induces Cardiac Dysfunction and Fibrosis.","date":"2024","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/38563133","citation_count":26,"is_preprint":false},{"pmid":"21105200","id":"PMC_21105200","title":"Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma.","date":"2010","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21105200","citation_count":26,"is_preprint":false},{"pmid":"23079193","id":"PMC_23079193","title":"Absence of Rgs5 prolongs cardiac repolarization and predisposes to ventricular tachyarrhythmia in mice.","date":"2012","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/23079193","citation_count":26,"is_preprint":false},{"pmid":"15670159","id":"PMC_15670159","title":"Identification of a novel alternative splicing variant of RGS5 mRNA in human ocular tissues.","date":"2005","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/15670159","citation_count":25,"is_preprint":false},{"pmid":"29208700","id":"PMC_29208700","title":"Hypertension-evoked RhoA activity in vascular smooth muscle cells requires RGS5.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29208700","citation_count":24,"is_preprint":false},{"pmid":"29061726","id":"PMC_29061726","title":"Angiotensin II Type 1 Receptor Mechanoactivation Involves RGS5 (Regulator of G Protein Signaling 5) in Skeletal Muscle Arteries: Impaired Trafficking of RGS5 in Hypertension.","date":"2017","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/29061726","citation_count":23,"is_preprint":false},{"pmid":"26558691","id":"PMC_26558691","title":"The pericyte antigen RGS5 in perivascular soft tissue tumors.","date":"2015","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26558691","citation_count":22,"is_preprint":false},{"pmid":"21389866","id":"PMC_21389866","title":"Combinational therapy of interferon-α and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma.","date":"2011","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/21389866","citation_count":20,"is_preprint":false},{"pmid":"34158395","id":"PMC_34158395","title":"ATE1 Inhibits Liver Cancer Progression through RGS5-Mediated Suppression of Wnt/β-Catenin Signaling.","date":"2021","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/34158395","citation_count":19,"is_preprint":false},{"pmid":"30365142","id":"PMC_30365142","title":"RGS5 decreases the proliferation of human ovarian carcinoma‑derived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30365142","citation_count":19,"is_preprint":false},{"pmid":"37674228","id":"PMC_37674228","title":"RGS5 augments astrocyte activation and facilitates neuroinflammation via TNF signaling.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37674228","citation_count":17,"is_preprint":false},{"pmid":"31605122","id":"PMC_31605122","title":"Down-regulated RGS5 by genetic variants impairs endothelial cell function and contributes to coronary artery disease.","date":"2021","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/31605122","citation_count":17,"is_preprint":false},{"pmid":"15680317","id":"PMC_15680317","title":"Beta adrenergic receptor-mediated atrial specific up-regulation of RGS5.","date":"2004","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15680317","citation_count":17,"is_preprint":false},{"pmid":"27189971","id":"PMC_27189971","title":"Vascular and Central Activation of Peroxisome Proliferator-Activated Receptor-β Attenuates Angiotensin II-Induced Hypertension: Role of RGS-5.","date":"2016","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27189971","citation_count":17,"is_preprint":false},{"pmid":"37986113","id":"PMC_37986113","title":"RGS5 maintaining vascular homeostasis is altered by the tumor microenvironment.","date":"2023","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/37986113","citation_count":16,"is_preprint":false},{"pmid":"32431860","id":"PMC_32431860","title":"RGS5 plays a significant role in renal cell carcinoma.","date":"2020","source":"Royal Society open science","url":"https://pubmed.ncbi.nlm.nih.gov/32431860","citation_count":15,"is_preprint":false},{"pmid":"36111549","id":"PMC_36111549","title":"RGS5: a novel role as a hypoxia-responsive protein that suppresses chemokinetic and chemotactic migration in brain pericytes.","date":"2022","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/36111549","citation_count":14,"is_preprint":false},{"pmid":"23144791","id":"PMC_23144791","title":"Atrial tachyarrhythmia in Rgs5-null mice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23144791","citation_count":14,"is_preprint":false},{"pmid":"37781234","id":"PMC_37781234","title":"Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection.","date":"2023","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/37781234","citation_count":14,"is_preprint":false},{"pmid":"24489801","id":"PMC_24489801","title":"Dlx1 and Rgs5 in the ductus arteriosus: vessel-specific genes identified by transcriptional profiling of laser-capture microdissected endothelial and smooth muscle cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24489801","citation_count":14,"is_preprint":false},{"pmid":"37881333","id":"PMC_37881333","title":"RGS5 as a Biomarker of Pericytes, Involvement in Vascular Remodeling and Pulmonary Arterial Hypertension.","date":"2023","source":"Vascular health and risk management","url":"https://pubmed.ncbi.nlm.nih.gov/37881333","citation_count":13,"is_preprint":false},{"pmid":"14504426","id":"PMC_14504426","title":"A culture device demonstrates that hydrostatic pressure increases mRNA of RGS5 in neuroblastoma and CHC1-L in lymphocytic cells.","date":"2003","source":"Cells, tissues, organs","url":"https://pubmed.ncbi.nlm.nih.gov/14504426","citation_count":13,"is_preprint":false},{"pmid":"17540411","id":"PMC_17540411","title":"Phosphorylation of Ser166 in RGS5 by protein kinase C causes loss of RGS function.","date":"2007","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17540411","citation_count":12,"is_preprint":false},{"pmid":"25810883","id":"PMC_25810883","title":"MicroRNAs that target RGS5.","date":"2015","source":"Iranian journal of basic medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25810883","citation_count":10,"is_preprint":false},{"pmid":"28684360","id":"PMC_28684360","title":"Regulator of G protein signaling 5 (RGS5) inhibits sonic hedgehog function in mouse cortical neurons.","date":"2017","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/28684360","citation_count":10,"is_preprint":false},{"pmid":"34359918","id":"PMC_34359918","title":"RGS5 Attenuates Baseline Activity of ERK1/2 and Promotes Growth Arrest of Vascular Smooth Muscle Cells.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34359918","citation_count":9,"is_preprint":false},{"pmid":"23637832","id":"PMC_23637832","title":"Regulator of G-protein signaling - 5 (RGS5) is a novel repressor of hedgehog signaling.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23637832","citation_count":9,"is_preprint":false},{"pmid":"27611366","id":"PMC_27611366","title":"Ruminal expression of the NQO1, RGS5, and ACAT1 genes may be indicators of feed efficiency in beef steers.","date":"2016","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27611366","citation_count":9,"is_preprint":false},{"pmid":"30690792","id":"PMC_30690792","title":"Parathyroid-Targeted Overexpression of Regulator of G-Protein Signaling 5 (RGS5) Causes Hyperparathyroidism in Transgenic Mice.","date":"2019","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/30690792","citation_count":8,"is_preprint":false},{"pmid":"37594134","id":"PMC_37594134","title":"Lnc‑RGS5 sponges miR‑542‑5p to promote FoxM1/VEGFA signaling and breast cancer cell proliferation.","date":"2023","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37594134","citation_count":7,"is_preprint":false},{"pmid":"35363396","id":"PMC_35363396","title":"NLGP regulates RGS5-TGFβ axis to promote pericyte-dependent vascular normalization during restricted tumor growth.","date":"2022","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35363396","citation_count":7,"is_preprint":false},{"pmid":"35522176","id":"PMC_35522176","title":"miR-320a Targeting RGS5 Aggravates Atherosclerosis by Promoting Migration and Proliferation of ox-LDL-Stimulated Vascular Smooth Muscle Cells.","date":"2022","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35522176","citation_count":6,"is_preprint":false},{"pmid":"26782409","id":"PMC_26782409","title":"Association of regulator of G protein signaling (RGS5) gene variants and essential hypertension in Mongolian and Han populations.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26782409","citation_count":6,"is_preprint":false},{"pmid":"36888549","id":"PMC_36888549","title":"Lineage Tracing of RGS5-CreER-Labeled Cells in Long Bones During Homeostasis and Injury.","date":"2023","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/36888549","citation_count":4,"is_preprint":false},{"pmid":"10733901","id":"PMC_10733901","title":"Molecular cloning and characterization of Xenopus RGS5.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10733901","citation_count":4,"is_preprint":false},{"pmid":"38860604","id":"PMC_38860604","title":"The mechanism of RGS5 regulating gastric cancer mismatch repair protein.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/38860604","citation_count":3,"is_preprint":false},{"pmid":"25842189","id":"PMC_25842189","title":"Regulation of RGS5 GAP activity by GPSM3.","date":"2015","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25842189","citation_count":3,"is_preprint":false},{"pmid":"23193110","id":"PMC_23193110","title":"RGS5 gene and therapeutic response to short acting bronchodilators in paediatric asthma patients.","date":"2012","source":"Pediatric pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/23193110","citation_count":3,"is_preprint":false},{"pmid":"34502263","id":"PMC_34502263","title":"RGS5 Determines Neutrophil Migration in the Acute Inflammatory Phase of Bleomycin-Induced Lung Injury.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34502263","citation_count":3,"is_preprint":false},{"pmid":"33815137","id":"PMC_33815137","title":"Absence of Rgs5 Influences the Spatial and Temporal Fluctuation of Cardiac Repolarization in Mice.","date":"2021","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33815137","citation_count":2,"is_preprint":false},{"pmid":"39746869","id":"PMC_39746869","title":"Germline deletion of Rgs2 and/or Rgs5 in male mice does not exacerbate left ventricular remodeling induced by subchronic isoproterenol infusion.","date":"2025","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/39746869","citation_count":2,"is_preprint":false},{"pmid":"17762159","id":"PMC_17762159","title":"Evidence for the dimerization of human regulator of G-protein signalling 5 (RGS5).","date":"2007","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17762159","citation_count":2,"is_preprint":false},{"pmid":"39985100","id":"PMC_39985100","title":"A pan-cancer analysis of the oncogenic and immunological roles of RGS5 in clear cell renal cell carcinomas based on in vitro experiment validation.","date":"2025","source":"Human genomics","url":"https://pubmed.ncbi.nlm.nih.gov/39985100","citation_count":1,"is_preprint":false},{"pmid":"32080025","id":"PMC_32080025","title":"RGS5 rs4657251 polymorphism is associated with small vessel occlusion stroke in Taiwan Han Chinese.","date":"2020","source":"Journal of the Chinese Medical Association : JCMA","url":"https://pubmed.ncbi.nlm.nih.gov/32080025","citation_count":1,"is_preprint":false},{"pmid":"35946384","id":"PMC_35946384","title":"Hypoxia-induced miR-182-5p regulates vascular smooth muscle cell phenotypic switch by targeting RGS5.","date":"2022","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/35946384","citation_count":1,"is_preprint":false},{"pmid":"40603753","id":"PMC_40603753","title":"Overexpression of MEOX2 inhibits breast cancer cell metastasis by targeting oxidative stress-induced RGS5.","date":"2025","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/40603753","citation_count":0,"is_preprint":false},{"pmid":"17100651","id":"PMC_17100651","title":"Expression, purification, and preliminary X-ray crystallographic analysis of the complex of G(alphai3)-RGS5 from human with GDP/Mg2+)/AlF4-.","date":"2006","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/17100651","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.20.639333","title":"Integrative Computational Analysis of VCX2 in Hepatocellular Carcinoma: From Potential Biomarker Discovery to Therapeutic Targeting with Peruvian Natural Products","date":"2025-02-26","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.20.639333","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41969,"output_tokens":8568,"usd":0.127214,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18337,"output_tokens":5420,"usd":0.113592,"stage2_stop_reason":"end_turn"},"total_usd":0.240806,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"RGS5 binds Gαi1, Gαi2, Gαi3, Gαo, and Gαq (but not Gαs or Gα13) in the presence of GDP/AlF4-, and accelerates GTP hydrolysis by Gαi3, functioning as a GAP for these G-protein subunits. RGS5 suppresses angiotensin II- and endothelin-1-induced intracellular Ca2+ transients in AT1a-expressing cells. The N-terminal region (aa 1-33) targets RGS5 to membranes but is not essential for GAP activity.\",\n      \"method\": \"In vitro GTP hydrolysis assay, Gα-binding assay with GDP/AlF4-, Ca2+ signaling assay in 293T cells, subcellular fractionation\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro GAP reconstitution plus cell-based functional assays and subcellular fractionation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"11253162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Endogenous RGS5 is a selective negative modulator of angiotensin AT1a receptor signaling through Gq/11 in rat vascular smooth muscle cells; RGS5 ribozyme knockdown specifically enhanced angiotensin II-induced MAP kinase activation and inositol phosphate release (pertussis toxin-insensitive), whereas RGS3 selectively modulated muscarinic m3 receptor signaling.\",\n      \"method\": \"Synthetic ribozyme-mediated knockdown, MAP kinase assay, inositol phosphate release assay in rat aortic smooth muscle cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function by ribozyme with specific phenotypic readout (MAPK, IP release), single lab, two orthogonal functional endpoints\",\n      \"pmids\": [\"12006602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RGS5 acts as a potent GAP for Gαi and Gαq and attenuates angiotensin II-, endothelin-1-, sphingosine-1-phosphate-, and PDGF-induced ERK-2 phosphorylation in pericytes/VSMCs. RGS5 expression is pericyte-specific and depends on PDGF-B/PDGFRβ signaling for pericyte recruitment but is expressed independently of this pathway once pericytes are present.\",\n      \"method\": \"ERK-2 phosphorylation assay, in situ hybridization, mouse genetic models (PDGFR-β and PDGF-B knockout)\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional signaling assay combined with genetic model evidence, single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"12514120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RGS5 is degraded in vivo through the N-end rule ubiquitin-proteasome pathway: ATE1 Arg-transferase arginylates oxidized N-terminal Cys-2 of RGS5, generating an N-degron recognized by ubiquitin ligases UBR1 and UBR2. Mutation of Cys-2 prevents this modification and stabilizes RGS5. Hypoxia or loss of UBR1/UBR2 perturbs this degradation.\",\n      \"method\": \"In vivo degradation assay in ATE1-/- and UBR1/UBR2-null cells, Cys-2 mutant analysis, protein stability assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mechanistic mutagenesis (C2 mutation), genetic knockouts of pathway components, replicated across multiple cell contexts in one rigorous study\",\n      \"pmids\": [\"16217033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A human-specific alternatively spliced variant of RGS5 (RGS5s) lacks the N-terminal 108 amino acids, localizes almost exclusively to the cytosol (unlike full-length RGS5 which is in both membrane and cytosolic fractions), inhibits Gαi-coupled receptor (CB1) signaling but not Gαq-coupled AT1 or FP receptor Ca2+ signaling. Co-expression of RGS5s with RGS5 blocks RGS5-mediated inhibition of AT1 and FP receptor signaling, suggesting a dominant-negative or competitive mechanism.\",\n      \"method\": \"RT-PCR cloning, subcellular fractionation, Ca2+ signaling assay, co-transfection in HEK293 cells\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation with functional consequence, co-expression competition assay, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"15670159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PKC phosphorylates RGS5 at Ser166 (identified by mass spectrometry), and this phosphorylation abolishes Gα-subunit binding and GAP activity. Substitution of Ser166 with aspartate (phospho-mimetic) markedly reduced inhibition of ET-1-induced Ca2+ responses; PKC inhibitors enhanced RGS5 inhibitory function.\",\n      \"method\": \"In vitro PKC phosphorylation assay, mass spectrometry, site-directed mutagenesis (S166D), Gα binding assay, Ca2+ signaling assay\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with MS identification of phospho-site, mutagenesis validation, cell-based functional readout; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"17540411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"N-terminal residues control proteasomal degradation of RGS5 in HEK293 cells; a stabilizing C2S mutation enhances RGS5 expression and function, whereas wild-type RGS5 has minimal cellular expression due to rapid N-end rule-mediated degradation.\",\n      \"method\": \"Mutagenesis, proteasome inhibitor treatment, expression/functional assays in HEK293 cells\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — mutagenesis and cell-based expression assay confirming N-end rule mechanism, single lab\",\n      \"pmids\": [\"17220356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The N-terminal amphipathic alpha-helix (aa 12-30) of RGS16 is required for plasma membrane association, and the hydrophobic residues on the nonpolar face plus positively charged residues at the polar/nonpolar interface are critical; RGS5 contains a homologous domain predicted to mediate membrane association by the same mechanism. RGS16 (and by homology RGS5) is a peripheral membrane protein not requiring palmitoylation.\",\n      \"method\": \"Site-directed mutagenesis, subcellular fractionation, differential centrifugation, alkaline wash (peripheral membrane protein characterization)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous mutagenesis and fractionation for RGS16, structural inference extended to RGS5 by homology without direct RGS5 experiments in this paper\",\n      \"pmids\": [\"10391923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Rgs5-deficient mice have persistently low blood pressure and dilated aortas. Isolated aortic smooth muscle cells from Rgs5-/- mice show exaggerated ERK phosphorylation and VASP phosphorylation in response to nitric oxide donor (sodium nitroprusside) or sphingosine-1-phosphate, indicating RGS5 attenuates vasodilatory signaling in vivo.\",\n      \"method\": \"Rgs5 knockout mouse, blood pressure telemetry, aortic morphometry, ex vivo smooth muscle cell signaling assays (western blot for pVASP, pERK)\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO mouse with defined vascular phenotype and ex vivo mechanistic signaling readouts, single lab, multiple orthogonal endpoints\",\n      \"pmids\": [\"18268011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Loss of Rgs5 in tumors results in pericyte maturation and vascular normalization (reduced vessel leakiness, reduced hypoxia), enhancing immune effector cell influx into tumors and prolonging survival of tumor-bearing mice, establishing RGS5 as a master regulator of abnormal tumor vascular morphology.\",\n      \"method\": \"Rgs5 knockout mouse in tumor models, MRI/histological vascular analysis, immune cell infiltration assay, survival analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with multiple functional vascular and immunological phenotypic readouts; high-impact replication context\",\n      \"pmids\": [\"18418378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Under hypoxia, RGS5 expression in endothelial cells is induced via HIF-1α-dependent transcription (RGS5 promoter activity is absent in HIF-1β-/- cells). RGS5 overexpression induces endothelial apoptosis via caspase-3 activation and increased Bax/Bcl-2 ratio. RGS5 augments VEGF-mediated p38 (but not ERK1/2) activation and impairs VEGF-induced angiogenesis in Matrigel assay.\",\n      \"method\": \"HIF-1β-/- cell promoter assay, RGS5 overexpression/siRNA knockdown in HUVEC, Annexin V apoptosis assay, caspase-3 activity assay, p38/ERK western blot, Matrigel angiogenesis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (HIF-1β-/-) plus OE/KD with multiple functional readouts, single lab\",\n      \"pmids\": [\"19564336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Beta-agonist treatment of human airway smooth muscle cells decreases RGS5 expression. RGS5 knockdown increases agonist-evoked intracellular calcium flux and myosin light chain phosphorylation. Airway smooth muscle from Rgs5-/- mice contracts more to carbachol than WT, establishing RGS5 as a negative regulator of bronchial smooth muscle contraction.\",\n      \"method\": \"siRNA knockdown in human airway smooth muscle cells, Ca2+ flux assay, MLC phosphorylation assay, precision-cut lung slice contraction in Rgs5-/- mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KD in human cells plus KO mouse tissue with consistent phenotypic readout across two systems; single lab but replicated across two orthogonal models\",\n      \"pmids\": [\"21278382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PPARγ and PPARδ each bind a PPAR response element near the RGS5 promoter and transcriptionally regulate RGS5 expression in vascular smooth muscle cells. RGS5, as a PPARγ/δ target, blunts angiotensin II-mediated PKC activation and preserves large-conductance Ca2+-activated K+ (BKCa) channel activity, controlling myogenic tone in resistance arteries.\",\n      \"method\": \"Chromatin reporter assay (PPRE), siRNA knockdown of RGS5, patch-clamp of BKCa current, myogenic tone measurement, transgenic dominant-negative PPARγ SMC mice, gene expression profiling\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — transcriptional mechanism (PPRE binding), patch-clamp electrophysiology, siRNA knockdown with functional phenotype, transgenic mouse model; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"22962432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Rgs5-/- mice show prolonged cardiac repolarization (prolonged QT interval and action potential duration) and increased susceptibility to ventricular tachyarrhythmia. This correlates with reduced outward K+ currents (Ito, IKur, Iss, Ipeak) and downregulated expression of Kv4.2, Kv4.3, Kv1.5, and Kv2.1 channels in ventricular myocytes.\",\n      \"method\": \"Rgs5 knockout mouse, in vivo/ex vivo electrocardiography, whole-cell patch clamp in ventricular myocytes, protein/mRNA expression analysis\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO mouse with patch-clamp electrophysiology defining K+ channel remodeling mechanism, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23079193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RGS5 is an endogenous repressor of Hedgehog signaling: RGS5 overexpression inhibits Shh-mediated signaling and osteogenesis, while siRNA knockdown of RGS5 (but not RGS4) potentiates Shh signaling. RGS5 co-localizes with Smoothened in primary cilia and co-immunoprecipitates with Smo, placing RGS5 downstream of Smo as a GAP for Gαi in the Hh pathway.\",\n      \"method\": \"RGS5 overexpression and siRNA knockdown in C3H10T1/2 cells, co-immunoprecipitation, immunohistochemistry of primary cilia, osteogenesis assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP showing physical complex with Smo, loss- and gain-of-function with defined signaling phenotype, single lab, two orthogonal methods\",\n      \"pmids\": [\"23637832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RGS5 is upregulated in vascular SMCs of remodeling collateral arterioles during arteriogenesis. RGS5 overexpression blunts Gαq/11-mediated Ca2+ mobilization and facilitates Gα12/13-mediated RhoA signaling, promoting SMC proliferation and acquisition of the activated phenotype required for collateral growth. RGS5 knockdown blocks RhoA activation, SMC proliferation, and collateral arteriole growth.\",\n      \"method\": \"RGS5 overexpression/knockdown in VSMCs, intracellular Ca2+ assay, RhoA activity assay (G-LISA/pull-down), mouse arteriogenesis model (femoral artery ligation), RGS5-deficient mice\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss- and gain-of-function with mechanistic signaling readouts (Ca2+, RhoA) in vitro plus in vivo arteriogenesis model, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24972930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPSM3 selectively binds RGS5 (not RGS4 or other RGS proteins tested) and enhances RGS5's ability to accelerate GTP hydrolysis by Gαi1 in solution-based assays. In membrane-based assays with M2 receptor-activated Gαi1, GPSM3 does not inhibit RGS5 GAP activity (unlike its effect on RGS4), suggesting binding of GPSM3 to RGS5 maintains or enhances GAP activity.\",\n      \"method\": \"Co-immunoprecipitation/pulldown, in vitro GTP hydrolysis assay (solution-based and membrane-based), primary rat aortic smooth muscle cell expression analysis\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro GAP assay with identified binding partner, single lab, no independent replication\",\n      \"pmids\": [\"25842189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In vascular smooth muscle cells, AT1R activation by angiotensin II or mechanical stimulation (hypotonic solution) induces translocation/trafficking of RGS5 toward the plasma membrane to co-localize with the activated AT1R (demonstrated by proximity ligation assay). RGS5 knockdown enhances constriction to angiotensin II and augments myogenic responses. This trafficking is impaired in VSMCs from spontaneously hypertensive rats.\",\n      \"method\": \"In situ proximity ligation assay, siRNA knockdown of RGS5 in arteriolar VSMCs, myogenic constriction measurement, intact arteriole contractility\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity ligation assay showing receptor-RGS5 interaction, siRNA KD with functional phenotype; single lab, two orthogonal methods\",\n      \"pmids\": [\"29061726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RGS5 inhibits Shh function in cortical neurons: RGS5 overexpression via adenovirus reduces neurite outgrowth and FM4-64 uptake (presynaptic terminal maturation marker), and affects cAMP-PKA signaling in cortical neurons, suggesting RGS5 acts as a Gαi GAP downstream of Smoothened in neuronal hedgehog signaling.\",\n      \"method\": \"Adenoviral RGS5 overexpression in primary cortical neurons, neurite outgrowth measurement, FM4-64 uptake assay, cAMP assay\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — gain-of-function with defined neuronal phenotypic readouts, single lab, single method per endpoint\",\n      \"pmids\": [\"28684360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Hypertensive pressure levels or biomechanical stretch increase RGS5 expression in VSMCs. RGS5 is required for hypertension-induced RhoA activation and stress fiber formation; RGS5-deficient VSMCs fail to acquire a synthetic phenotype (cannot downregulate α-SMA, smooth muscle-MHC, or proliferate) under hypertensive conditions. PKC inhibition mimics the downstream effect of RGS5-mediated Gαq/11 inhibition, amplifying RhoA activity.\",\n      \"method\": \"RGS5-deficient mice with experimental hypertension (angiotensin II infusion), mechanical stretch assay in VSMCs, RhoA activity assay, contractile marker western blot, PKC inhibitor experiments\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse plus in vitro stretch/pharmacological dissection with mechanistic pathway (RhoA/PKC), single lab, multiple orthogonal methods\",\n      \"pmids\": [\"29208700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RGS5 binds Gαi/q and promotes pericyte apoptosis in vitro by blocking PI3K-AKT signaling, leading to Bcl2 downregulation and PUMA-p53-Bax-mediated mitochondrial damage. Within the tumor microenvironment, TGFβ causes pSmad2 to bind RGS5 and translocate it to the nucleus, suppressing both RGS5-Gαi/q interaction and pSmad2/3-Smad4 pairing, thereby rescuing PI3K-AKT survival signaling and preventing apoptosis in tumor pericytes.\",\n      \"method\": \"Co-immunoprecipitation of RGS5 with Gαi/q and pSmad2, nuclear fractionation, PI3K-AKT/Bcl2/Bax western blot, caspase assay, siRNA/overexpression in pericytes, TGFβ treatment\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying molecular complex, nuclear translocation, multiple signaling pathway readouts; single lab, several orthogonal methods\",\n      \"pmids\": [\"34012071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ATE1-mediated arginylation controls RGS5 protein turnover and thereby regulates Wnt/β-catenin signaling in liver cancer cells: ATE1 overexpression accelerates β-catenin degradation through RGS5-dependent regulation of GSK3-β activity; RGS5 knockdown reverses ATE1-mediated suppression of Wnt signaling. Co-immunoprecipitation confirms RGS5 interaction with components of this pathway.\",\n      \"method\": \"ATE1/RGS5 loss- and gain-of-function in HCC cells, β-catenin western blot, GSK3-β activity assay, GSK inhibitor rescue experiment, co-immunoprecipitation\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis experiments placing RGS5 between ATE1 and Wnt/β-catenin, Co-IP, GSK inhibitor rescue; single lab\",\n      \"pmids\": [\"34158395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RGS5 overexpression in proliferating VSMCs attenuates ERK1/2 and Akt signaling, reduces proliferation and migration; this effect is mimicked by selective Gαi/o inhibition but not by Gαq/11 inhibition, indicating RGS5 maintains VSMC resting state principally by suppressing Gαi/o-mediated ERK1/2 activation.\",\n      \"method\": \"RGS5 overexpression in 2D-cultured VSMCs, Gαi/o- and Gαq/11-selective inhibitors, ERK1/2/Akt phosphorylation western blot, proliferation and migration assays, microarray expression profiling\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of G-protein subtype specificity combined with OE and functional readouts; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"34359918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RGS5 deletion in neutrophils impairs their migration toward chemokines despite preserved Ca2+ signaling; ERK dephosphorylation is implicated in reduced neutrophil migration. In vivo, RGS5-/- mice fail to recruit neutrophils to the lung after bleomycin or LPS injury, preserving lung function.\",\n      \"method\": \"RGS5-/- mouse lung injury models (bleomycin, LPS), in vitro neutrophil migration assay, Ca2+ signaling measurement, ERK phosphorylation western blot, myeloperoxidase measurement\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse plus in vitro mechanistic dissection (Ca2+, ERK) of migration defect; single lab\",\n      \"pmids\": [\"34502263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In astrocytes, RGS5 promotes neuroinflammation by binding directly to TNFR1 and TNFR2 (shown by Co-IP), augmenting TNF receptor signaling and switching astrocytes from neuroprotective to pro-inflammatory. Selective ablation of Rgs5 in astrocytes inhibits cytokine production and is neuroprotective in PD models; the RGS5 aa 1-108 fragment or small molecules (feshurin, butein) that disrupt RGS5/TNFR interaction suppress astrocytic cytokine production.\",\n      \"method\": \"Conditional astrocyte-specific Rgs5 knockout, RGS5 overexpression, Co-IP of RGS5 with TNFR1/TNFR2, cytokine ELISA, PD mouse models, competitive peptide/small molecule inhibition\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO plus reciprocal Co-IP showing direct protein-protein interaction with TNFRs plus pharmacological disruption; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37674228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RGS5 in cardiac pericytes is reduced with aging. Deletion of RGS5 causes cardiac dysfunction and myocardial fibrosis by inducing a profibrotic gene signature in pericytes (upregulating TGFB2, PDGFB, ECM components). Conditioned medium from RGS5-deficient pericytes activates adjacent fibroblasts (increased αSMA) via a TGFβ2-dependent mechanism.\",\n      \"method\": \"Pericyte-specific RGS5 deletion in mice, single-nucleus RNA sequencing, pericyte-fibroblast co-culture, conditioned medium experiments, αSMA/TGFβ2 western blot, cardiac function echocardiography, fibrosis histology\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO phenotype plus mechanistic co-culture demonstrating TGFβ2-dependent paracrine fibroblast activation, snRNA-seq; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38563133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RGS5 overexpression in parathyroid cells inhibits calcium-sensing receptor (CASR) signaling and impairs negative feedback on PTH secretion. Transgenic mice overexpressing RGS5 specifically in parathyroid glands develop hyperparathyroidism, bone changes, and parathyroid neoplasia, establishing RGS5 as an inhibitor of CASR-mediated signaling in parathyroid physiology.\",\n      \"method\": \"Parathyroid-specific RGS5 transgenic mouse, PTH measurement, bone analysis, parathyroid histology, CASR signaling assay in normal human parathyroid cells expressing RGS5\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic gain-of-function mouse with organ-specific phenotype plus cell-based CASR signaling assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"30690792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The complex of human Gαi3 and RGS5 was crystallized with GDP/Mg2+/AlF4- at 3.0 Å resolution (space group P4(1)2(1)2 or P4(3)2(1)2), providing preliminary structural data for the RGS5-Gα interaction.\",\n      \"method\": \"Recombinant protein expression in E. coli, protein purification, X-ray crystallography (synchrotron, 3.0 Å)\",\n      \"journal\": \"Protein and peptide letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 1 / Weak — preliminary crystallization report without full structural analysis or functional validation; single paper, no replication\",\n      \"pmids\": [\"17100651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RGS5 forms homodimers detectable by western blot (~42 kDa band) and confirmed by yeast two-hybrid and GFP-tagged RGS5 analysis in HEK293A cells. The dimer is longer-lived than the monomer, suggesting a regulatory function.\",\n      \"method\": \"Western blot of overexpressed RGS5, yeast two-hybrid assay, GFP-RGS5 fusion analysis in yeast and HEK293A cells\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast two-hybrid and western blot evidence for dimerization, functional significance not established; single lab, single study\",\n      \"pmids\": [\"17762159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Rgs5 expression shows vascular bed-specific differences in adult mice driven by an origin-specific epigenetic program: the Rgs5 promoter is more heavily methylated at CpG dinucleotides in carotid artery (neural crest-derived) VSMCs compared to descending aorta VSMCs in adults but not neonates. In vitro methylation of the Rgs5 promoter confirmed transcriptional repression by CpG methylation.\",\n      \"method\": \"Rgs5-LacZ reporter mouse (lineage mapping), bisulfite sequencing of Rgs5 promoter, in vitro methylation reporter assay, primary VSMC culture\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — bisulfite sequencing identifying specific CpG methylation plus in vitro promoter methylation functional assay plus LacZ reporter in vivo; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21965603\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RGS5 is a GTPase-activating protein (GAP) for Gαi and Gαq subunits, expressed predominantly in pericytes and vascular smooth muscle cells, whose protein stability is regulated by the N-end rule pathway (ATE1-mediated arginylation of oxidized Cys-2 followed by UBR1/UBR2-dependent ubiquitination and proteasomal degradation); PKC phosphorylation at Ser166 inactivates its GAP function; in VSMCs it suppresses Gαq/11-mediated calcium signaling while enabling Gα12/13/RhoA-dependent SMC activation, thereby regulating arterial tone, vascular remodeling, arteriogenesis, and hypertension responses; in pericytes it controls vessel maturation, tumor vascular morphology, and cardiac homeostasis partly through TGFβ/Smad2-regulated nuclear trafficking; and in non-vascular contexts it functions as a repressor of Hedgehog/Gαi signaling and, in astrocytes, augments TNF receptor signaling through direct TNFR1/TNFR2 binding to promote neuroinflammation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RGS5 is a GTPase-activating protein (GAP) that accelerates GTP hydrolysis by Gαi and Gαq subunits and thereby acts as a negative regulator of G-protein-coupled receptor signaling, with a predominant role in vascular smooth muscle and pericyte biology [#0, #2]. Through GAP activity on Gαq/11 it dampens angiotensin II- and endothelin-1-evoked intracellular Ca2+ transients and downstream MAPK signaling in vascular smooth muscle cells [#0, #1, #2], and upon receptor activation or mechanical stimulation it traffics to the plasma membrane to co-localize with the activated AT1 receptor [#17]. In vivo, RGS5 sets vascular tone and blood pressure: Rgs5-null mice are hypotensive with dilated aortas and show exaggerated vasodilatory ERK/VASP signaling [#8], while in resistance arteries RGS5 (a transcriptional target of PPARγ/δ) blunts angiotensin II-driven PKC activation and preserves BKCa channel activity to control myogenic tone [#12]. By simultaneously suppressing Gαq/11-Ca2+ signaling and licensing Gα12/13-RhoA signaling, RGS5 drives the phenotypic switch of smooth muscle cells required for arteriogenesis and hypertensive remodeling [#15, #19]. In pericytes RGS5 governs tumor vessel morphology—its loss promotes pericyte maturation, vascular normalization, and enhanced anti-tumor immune infiltration [#9]—and it controls pericyte survival and cardiac homeostasis, where TGFβ-driven pSmad2 binding redirects RGS5 to the nucleus to rescue PI3K-AKT survival signaling, and where pericyte RGS5 loss elicits a TGFβ2-dependent profibrotic program [#20, #25]. RGS5 protein abundance is tightly governed by the N-end rule pathway: ATE1 arginylates oxidized N-terminal Cys-2 to generate an N-degron recognized by the UBR1/UBR2 ubiquitin ligases for proteasomal degradation, and a stabilizing Cys-2 mutation increases RGS5 expression and function [#3, #6]. GAP activity is further switched off by PKC phosphorylation at Ser166, which abolishes Gα binding [#5]. Beyond the vasculature, RGS5 represses Hedgehog/Gαi signaling in association with Smoothened at the primary cilium [#14], and in astrocytes it binds TNFR1 and TNFR2 directly to augment TNF receptor signaling and promote neuroinflammation [#24].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established RGS5's core biochemical identity by showing it is a GAP selective for Gαi and Gαq subunits that dampens receptor-evoked calcium signaling, defining the molecular activity all later vascular roles build on.\",\n      \"evidence\": \"In vitro GTP hydrolysis and Gα-binding assays plus Ca2+ signaling and fractionation in 293T cells\",\n      \"pmids\": [\"11253162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the physiological receptor/tissue context\", \"Membrane-targeting role of N-terminus separated from GAP catalysis but not structurally resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed endogenous RGS5 selectively constrains AT1 receptor-Gq/11 signaling in vascular smooth muscle, moving from biochemistry to a defined endogenous receptor target.\",\n      \"evidence\": \"Ribozyme knockdown with MAPK and inositol phosphate readouts in rat aortic smooth muscle cells\",\n      \"pmids\": [\"12006602\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single loss-of-function approach\", \"In vivo relevance not yet tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined RGS5 as a pericyte-specific gene downstream of PDGF-B/PDGFRβ-driven pericyte recruitment, localizing its biology to the pericyte/VSMC compartment.\",\n      \"evidence\": \"ERK assays, in situ hybridization, and PDGFRβ/PDGF-B knockout mice\",\n      \"pmids\": [\"12514120\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling pericyte identity to RGS5 transcription unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed that RGS5 abundance is controlled post-translationally by the N-end rule pathway via ATE1 arginylation of oxidized Cys-2 and UBR1/UBR2-dependent ubiquitination, explaining its normally low cellular levels and oxygen sensitivity.\",\n      \"evidence\": \"In vivo degradation assays in ATE1-/- and UBR1/UBR2-null cells with Cys-2 mutagenesis\",\n      \"pmids\": [\"16217033\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How physiological hypoxia tunes RGS5 stability in vascular cells not directly measured\", \"Did not link degradation rate to a specific GAP-dependent phenotype\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified a human-specific cytosolic splice variant lacking the N-terminal 108 residues that selectively inhibits Gαi signaling and can competitively block full-length RGS5, introducing isoform-level regulation of GAP specificity.\",\n      \"evidence\": \"RT-PCR cloning, fractionation, and co-transfection Ca2+ assays in HEK293 cells\",\n      \"pmids\": [\"15670159\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous abundance and in vivo role of the variant unknown\", \"Dominant-negative mechanism inferred from overexpression\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed PKC phosphorylation at Ser166 abolishes Gα binding and GAP activity, providing an acute signaling switch that inactivates RGS5 independent of its degradation.\",\n      \"evidence\": \"In vitro PKC kinase assay, mass spectrometry, S166D mutant, and Ca2+ signaling readouts\",\n      \"pmids\": [\"17540411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which receptors/PKC isoforms drive Ser166 phosphorylation in vivo not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated in vivo that RGS5 sets blood pressure and vascular tone, with knockout causing hypotension, aortic dilation, and exaggerated vasodilatory signaling.\",\n      \"evidence\": \"Rgs5 knockout mice with telemetry, morphometry, and ex vivo pVASP/pERK signaling\",\n      \"pmids\": [\"18268011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor coupling underlying enhanced NO/S1P responses not pinpointed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established RGS5 as a master regulator of abnormal tumor vasculature, where its loss normalizes vessels and improves immune infiltration and survival.\",\n      \"evidence\": \"Rgs5 knockout tumor models with vascular imaging, immune infiltration, and survival analysis\",\n      \"pmids\": [\"18418378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-autonomous pericyte signaling driving normalization not dissected in this study\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed RGS5 in transcriptional and electrophysiological control of myogenic tone as a PPARγ/δ target that preserves BKCa channel activity by limiting angiotensin II-PKC signaling.\",\n      \"evidence\": \"PPRE reporter, siRNA, BKCa patch-clamp, myogenic tone, and dominant-negative PPARγ mice\",\n      \"pmids\": [\"22962432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct link from RGS5 GAP activity to BKCa modulation mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Resolved the dual G-protein logic of RGS5 in arteriogenesis: it suppresses Gαq/11-Ca2+ while facilitating Gα12/13-RhoA signaling to drive the activated, proliferative SMC phenotype.\",\n      \"evidence\": \"Gain/loss-of-function in VSMCs with Ca2+ and RhoA assays plus a femoral ligation arteriogenesis model\",\n      \"pmids\": [\"24972930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a GAP promotes rather than inhibits Gα12/13-RhoA signaling not mechanistically explained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended the RhoA-licensing role to hypertensive remodeling, showing RGS5 is required for stress-fiber formation and synthetic phenotype switching under pressure.\",\n      \"evidence\": \"RGS5-deficient mice with angiotensin II infusion, stretch assays, RhoA activity, and PKC inhibition\",\n      \"pmids\": [\"29208700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether nuclear or membrane RGS5 mediates the remodeling phenotype unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked RGS5 function to receptor-triggered subcellular trafficking, showing it moves to the activated AT1R at the membrane and that this trafficking is impaired in hypertensive vessels.\",\n      \"evidence\": \"Proximity ligation assay and siRNA knockdown with myogenic constriction in arteriolar VSMCs\",\n      \"pmids\": [\"29061726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular driver of RGS5 translocation not identified\", \"Correlative link to hypertension\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified GPSM3 as a selective RGS5-binding partner that maintains or enhances RGS5 GAP activity, distinguishing RGS5 regulation from other RGS proteins.\",\n      \"evidence\": \"Co-IP/pulldown and solution/membrane GTP hydrolysis assays\",\n      \"pmids\": [\"25842189\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No independent replication\", \"Physiological consequence of GPSM3-RGS5 complex not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a tumor-microenvironment switch in which TGFβ-driven pSmad2 binds RGS5 and translocates it to the nucleus, releasing Gαi/q to rescue PI3K-AKT survival signaling in pericytes.\",\n      \"evidence\": \"Co-IP of RGS5 with Gαi/q and pSmad2, nuclear fractionation, and apoptosis/PI3K-AKT readouts in pericytes\",\n      \"pmids\": [\"34012071\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct demonstration that nuclear sequestration causes the survival phenotype is indirect\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected pericyte RGS5 loss to cardiac dysfunction and fibrosis via a TGFβ2-dependent paracrine profibrotic program, extending its pericyte role to organ homeostasis.\",\n      \"evidence\": \"Pericyte-specific RGS5 deletion, snRNA-seq, and pericyte-fibroblast co-culture/conditioned medium experiments\",\n      \"pmids\": [\"38563133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How RGS5 GAP activity represses the profibrotic transcriptional program not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Placed RGS5 outside the vasculature as an endogenous Hedgehog repressor acting as a Gαi GAP in complex with Smoothened at the primary cilium.\",\n      \"evidence\": \"Overexpression/siRNA, Co-IP with Smo, and ciliary co-localization in C3H10T1/2 cells\",\n      \"pmids\": [\"23637832\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct GAP action on Smo-coupled Gαi at the cilium inferred, not biochemically reconstituted\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed a non-GAP signaling role in astrocytes where RGS5 binds TNFR1/TNFR2 directly to augment TNF signaling and drive neuroinflammation, identifying a druggable protein-protein interaction.\",\n      \"evidence\": \"Astrocyte-specific knockout, reciprocal Co-IP with TNFRs, PD models, and peptide/small-molecule disruption\",\n      \"pmids\": [\"37674228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of RGS5-TNFR binding undefined\", \"Relationship between TNFR binding and canonical GAP activity unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How RGS5 reconciles its dual roles as a GAP that both inhibits (Gαq/11, Gαi) and enables (Gα12/13-RhoA) signaling, and how its trafficking, dimerization, and non-GAP TNFR/Smo binding are integrated at the structural level, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full atomic-resolution RGS5-Gα structure analyzed beyond preliminary crystallization\", \"Functional significance of RGS5 homodimerization unestablished\", \"Mechanism by which a GAP facilitates Gα12/13-RhoA signaling unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2, 5, 16]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 14, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 7, 17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0005929\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 14, 15]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"R-HSA-397014\", \"supporting_discovery_ids\": [11, 12, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [24, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GNAI1\", \"GNAI3\", \"GNAQ\", \"GPSM3\", \"SMO\", \"TNFRSF1A\", \"TNFRSF1B\", \"SMAD2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}